Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations.

Authors:
Heejin Bang Heejung Park Sanghui Park Euno Choi Min-Sun Cho Sun Hee Sung Sun Young Choi Yong Mee Cho Se Un Jeong Jae Y Ro

Ann Diagn Pathol 2020 Feb 22;44:151433. Epub 2019 Nov 22.

Department of Pathology and Genomic Medicine, The Methodist Hospital and Weill Medical College of Cornell University, Houston, TX 77030, USA. Electronic address:

Background: Most urothelial neoplasms of the bladder show an exophytic papillary pattern, but some show an inverted growth pattern. In 2004, the World Health Organization (WHO) released a detailed histologic classification system for papillary urothelial neoplasms, but not for inverted forms. The International Consultation on Urologic Disease (ICUD) recommendations of 2012 are applicable to inverted/endophytic papillary lesions as follows: 1) inverted papilloma (IP), 2) inverted papillary urothelial neoplasm of low malignant potential (IPUNLMP), 3) inverted papillary urothelial carcinoma, low grade, non-invasive (IPUCLG-NI), 4) inverted papillary urothelial carcinoma, high grade, non-invasive (IPUCHG-NI), 5) inverted papillary urothelial carcinoma, high grade, invasive (IPUCHG-I). However, only atypical cellular morphology was considered for classification in the 2012 ICUD recommendations, and data to support to validate this new grading system are lacking.

Methods: Sixty cases of inverted urothelial papillary tumors were classified into 5 categories according to 2012 ICUD and 2016 WHO/ISUP recommendations to evaluate their clinical, pathological, and immunohistochemical characteristics. Two subgroups were defined as subgroup 1, IP and IPUNLMP, and subgroup 2, IPUCLG-NI, IPUCHG-NI, and IPUCHG-I. Clinical features (age, sex, history of urothelial carcinoma, smoking history, size, and multifocality) and histologic features (nuclear pleomorphism, mitotic count, mitosis level, apoptosis, luminal necrosis, trabecular thickening, anastomosing trabeculae, hypercellularity, loss of polarity, peripheral palisading, palisading with central streaming, and discohesiveness) were evaluated. Immunohistochemical stains for CK20, CD44, P53, p16, Ki-67, cyclin D1 and c-erbB2 were performed.

Results: A total of 60 cases were classified as 10 cases of IP, 29 cases of IPUNLMPs, 15 cases of IPUCLG-NI, 4 cases of IPUCHG-NI, and 2 cases of IPUCHG-I. Compared to subgroup 1, subgroup 2 showed larger tumor size, more nuclear irregularity, higher mitotic count (hot spot and per 10 high power fields), more upper level mitosis (>1/2), and more frequent apoptosis, luminal necrosis, surface papillary component, trabecular thickening, anastomosing irregular trabeculae, hypercellularity, loss of polarity, peripheral palisading with central streaming, and discohesiveness, and absence of umbrella cells and urothelial eddies. CK20, Ki67, and c-erbB2 were the only markers that were differently expressed in the two subgroups, with more expression in subgroup 2.

Conclusions: The 2012 ICUD recommendations are valid to classify inverted papillary urothelial tumors. However, other histologic features besides atypical cellular morphology should also be considered to distinguish subgroup 1 and subgroup 2 inverted papillary urothelial tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.151433DOI Listing
February 2020

Publication Analysis

Top Keywords

papillary urothelial
28
inverted papillary
24
icud recommendations
16
urothelial carcinoma
16
urothelial
12
urothelial neoplasms
12
2012 icud
12
papillary
11
inverted
11
palisading central
8
disease icud
8
atypical cellular
8
central streaming
8
apoptosis luminal
8
histologic features
8
carcinoma high
8
urologic disease
8
high grade
8
peripheral palisading
8
polarity peripheral
8

Keyword Occurance

Similar Publications

Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors.

Authors:
Anne Menz Natalia Gorbokon Florian Viehweger Maximilian Lennartz Claudia Hube-Magg Lisa Hornsteiner Martina Kluth Cosima Völkel Andreas M Luebke Christoph Fraune Ria Uhlig Sarah Minner David Dum Doris Höflmayer Guido Sauter Ronald Simon Eike Burandt Till S Clauditz Patrick Lebok Frank Jacobsen Stefan Steurer Till Krech Andreas H Marx Christian Bernreuther

Int J Surg Pathol 2022 Aug 9:10668969221117243. Epub 2022 Aug 9.

Institute of Pathology, 37734University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

To evaluate the efficiency of pan-keratin immunostaining, tissue microarrays of 13,501 tumor samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. In normal tissues, strong pan-keratin immunostaining was seen in epithelial cells. Staining intensity was lower in hepatocytes, islets of Langerhans, and pneumocytes but markedly reduced in the adrenal cortex. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Castration immunoregulates toll-like receptor-4 in male bladder cancer.

Authors:
Leonardo Oliveira Reis Ana Clara Ciglioni Salustiano Diego Moreira Capibaribe Isis Gallani Avansini Kiehl Fernandes Denardi

Int Urol Nephrol 2022 Aug 8. Epub 2022 Aug 8.

UroScience, School of Medical Sciences, State University of Campinas, UNICAMP, Campinas, SP, Brazil.

Purpose: Among diverse Pattern Recognition Receptors (PRRs), Toll-like receptor-4 (TLR-4) is a key urothelial trigger for innate immune response impacting urothelial bladder carcinoma (BC). Androgen activation promotes immunotolerance, playing an immunoregulatory role by unknown mechanisms. We explored the castration impact on urothelial TLR-4 modulation in carcinogenesis and immunotherapeutic scenario. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow.

Authors:
Zhangli Su Ida Monshaugen Arne Klungland Rune Ougland Anindya Dutta

Front Mol Biosci 2022 18;9:887686. Epub 2022 Jul 18.

Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, United States.

Bladder cancer (BLCA) is one of the most common cancer types worldwide. The disease is responsible for about 200,000 deaths annually, thus improved diagnostics and therapy is needed. A large body of evidence reveal that small RNAs of less than 40 nucleotides may act as tumor suppressors, oncogenes, and disease biomarkers, with a major focus on microRNAs. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

A Pan-Cancer Analysis of the Oncogenic Role of : A Potential Biomarker for Prognosis and Immunotherapy.

Authors:
Dinglong Yang Hetong Li Yujing Chen Chunjiang Li Weiping Ren Yongbo Huang

Front Genet 2022 15;13:906174. Epub 2022 Jul 15.

Department of Orthopedics, The Second Hospital of Shanxi Medical University, Taiyuan, China.

Previous studies have partly explored the role of B-cell CLL/lymphoma 7 protein family member B () in tumorigenesis and development. However, the prognosis and immunoregulatory value of in pan-cancer patients remains unclear. Through The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, the distinct expression of gene in 33 tumors and adjacent normal tissues was analyzed. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.

Authors:
Ivonne A Montes-Mojarro Saki Hassas Sina Staehle Philip Sander Niklas Harland Lina Maria Serna-Higuita Irina Bonzheim Hans Bösmüller Arnulf Stenzl Falko Fend

Int J Mol Sci 2022 Jul 23;23(15). Epub 2022 Jul 23.

Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tuebingen, Eberhard-Karls-University, 72076 Tuebingen, Germany.

Diagnosis and grading of non-invasive papillary urothelial tumors according to the current WHO classification poses some challenges for pathologists. The diagnostic reproducibility of separating low-grade and high-grade lesions is low, which impacts their clinical management. Whereas papillary urothelial neoplasms with low malignant potential (PUN-LMP) and low-grade papillary non-invasive carcinoma (LG-PUC) are comparable and show frequent local recurrence but rarely metastasize, high-grade papillary non-invasive carcinoma (HG-PUC) has a poor prognosis. Read More

View Article and Full-Text PDF
July 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap